Usefulness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients for unresectable biliary carcinoma

Yuji Morine, Mitsuo Shimada, Toru Ikegami, Satoru Imura, Hirohumi Kanemura, Yusuke Arakawa, Jun Hanaoka, Mami Kanamoto, Akira Nii

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background/Aii Advanced biliary carcinoma have poor prognosis and chemotherapy has been shown to have little imapact The aim of the present study is to clarify the effectiveness of GEM combined with CDDP and 5FU (GFP) therapy for unre-sectahtebStarYcansaoma. Meihodologyi Fourteen patients with biliary carcinoma (4 patients; gaSbkdder cancer, 10 patients; biliary tract) who had no prior chemotherapy were enrolled. A triple combination of agents was administered with a 4-week cycle GP chemotherapy consisting of GEM at l000ingIm2 on days 1 and of 5-FU 250mg1m2 and CDDP at 3mgIm2 on days 1 to 5. Results: No patient achieved CR, while five patients achieved PR as assessed by RECIST. The overall response rate from the intent-to-treat analysis was 21.4%. Stable disease was observed in 9 (64.3%) patients. Clinical benefit rate was observed in 14 (85.7%) patients. According to the tumor site, overall response rate waa 20.0% in biliary tract car-cktoma. Conclusions: The significant antitumor activity of GFP chemotherapy has been seen in patients with advanced biliary carcinoma. However, further evaluation in large numbers of patients is needed to determine the difference in chemosensitivity according to the tumor site.

Original languageEnglish
Pages (from-to)307-312
Number of pages6
JournalHepato-gastroenterology
Volume56
Issue number90
Publication statusPublished - Mar 1 2009

Fingerprint

gemcitabine
Fluorouracil
Cisplatin
Carcinoma
Drug Therapy
Biliary Tract
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Usefulness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients for unresectable biliary carcinoma. / Morine, Yuji; Shimada, Mitsuo; Ikegami, Toru; Imura, Satoru; Kanemura, Hirohumi; Arakawa, Yusuke; Hanaoka, Jun; Kanamoto, Mami; Nii, Akira.

In: Hepato-gastroenterology, Vol. 56, No. 90, 01.03.2009, p. 307-312.

Research output: Contribution to journalArticle

Morine, Y, Shimada, M, Ikegami, T, Imura, S, Kanemura, H, Arakawa, Y, Hanaoka, J, Kanamoto, M & Nii, A 2009, 'Usefulness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients for unresectable biliary carcinoma', Hepato-gastroenterology, vol. 56, no. 90, pp. 307-312.
Morine, Yuji ; Shimada, Mitsuo ; Ikegami, Toru ; Imura, Satoru ; Kanemura, Hirohumi ; Arakawa, Yusuke ; Hanaoka, Jun ; Kanamoto, Mami ; Nii, Akira. / Usefulness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients for unresectable biliary carcinoma. In: Hepato-gastroenterology. 2009 ; Vol. 56, No. 90. pp. 307-312.
@article{fc9ec641a3d04208a6c0228fdd6f2fb6,
title = "Usefulness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients for unresectable biliary carcinoma",
abstract = "Background/Aii Advanced biliary carcinoma have poor prognosis and chemotherapy has been shown to have little imapact The aim of the present study is to clarify the effectiveness of GEM combined with CDDP and 5FU (GFP) therapy for unre-sectahtebStarYcansaoma. Meihodologyi Fourteen patients with biliary carcinoma (4 patients; gaSbkdder cancer, 10 patients; biliary tract) who had no prior chemotherapy were enrolled. A triple combination of agents was administered with a 4-week cycle GP chemotherapy consisting of GEM at l000ingIm2 on days 1 and of 5-FU 250mg1m2 and CDDP at 3mgIm2 on days 1 to 5. Results: No patient achieved CR, while five patients achieved PR as assessed by RECIST. The overall response rate from the intent-to-treat analysis was 21.4{\%}. Stable disease was observed in 9 (64.3{\%}) patients. Clinical benefit rate was observed in 14 (85.7{\%}) patients. According to the tumor site, overall response rate waa 20.0{\%} in biliary tract car-cktoma. Conclusions: The significant antitumor activity of GFP chemotherapy has been seen in patients with advanced biliary carcinoma. However, further evaluation in large numbers of patients is needed to determine the difference in chemosensitivity according to the tumor site.",
author = "Yuji Morine and Mitsuo Shimada and Toru Ikegami and Satoru Imura and Hirohumi Kanemura and Yusuke Arakawa and Jun Hanaoka and Mami Kanamoto and Akira Nii",
year = "2009",
month = "3",
day = "1",
language = "English",
volume = "56",
pages = "307--312",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "90",

}

TY - JOUR

T1 - Usefulness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients for unresectable biliary carcinoma

AU - Morine, Yuji

AU - Shimada, Mitsuo

AU - Ikegami, Toru

AU - Imura, Satoru

AU - Kanemura, Hirohumi

AU - Arakawa, Yusuke

AU - Hanaoka, Jun

AU - Kanamoto, Mami

AU - Nii, Akira

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Background/Aii Advanced biliary carcinoma have poor prognosis and chemotherapy has been shown to have little imapact The aim of the present study is to clarify the effectiveness of GEM combined with CDDP and 5FU (GFP) therapy for unre-sectahtebStarYcansaoma. Meihodologyi Fourteen patients with biliary carcinoma (4 patients; gaSbkdder cancer, 10 patients; biliary tract) who had no prior chemotherapy were enrolled. A triple combination of agents was administered with a 4-week cycle GP chemotherapy consisting of GEM at l000ingIm2 on days 1 and of 5-FU 250mg1m2 and CDDP at 3mgIm2 on days 1 to 5. Results: No patient achieved CR, while five patients achieved PR as assessed by RECIST. The overall response rate from the intent-to-treat analysis was 21.4%. Stable disease was observed in 9 (64.3%) patients. Clinical benefit rate was observed in 14 (85.7%) patients. According to the tumor site, overall response rate waa 20.0% in biliary tract car-cktoma. Conclusions: The significant antitumor activity of GFP chemotherapy has been seen in patients with advanced biliary carcinoma. However, further evaluation in large numbers of patients is needed to determine the difference in chemosensitivity according to the tumor site.

AB - Background/Aii Advanced biliary carcinoma have poor prognosis and chemotherapy has been shown to have little imapact The aim of the present study is to clarify the effectiveness of GEM combined with CDDP and 5FU (GFP) therapy for unre-sectahtebStarYcansaoma. Meihodologyi Fourteen patients with biliary carcinoma (4 patients; gaSbkdder cancer, 10 patients; biliary tract) who had no prior chemotherapy were enrolled. A triple combination of agents was administered with a 4-week cycle GP chemotherapy consisting of GEM at l000ingIm2 on days 1 and of 5-FU 250mg1m2 and CDDP at 3mgIm2 on days 1 to 5. Results: No patient achieved CR, while five patients achieved PR as assessed by RECIST. The overall response rate from the intent-to-treat analysis was 21.4%. Stable disease was observed in 9 (64.3%) patients. Clinical benefit rate was observed in 14 (85.7%) patients. According to the tumor site, overall response rate waa 20.0% in biliary tract car-cktoma. Conclusions: The significant antitumor activity of GFP chemotherapy has been seen in patients with advanced biliary carcinoma. However, further evaluation in large numbers of patients is needed to determine the difference in chemosensitivity according to the tumor site.

UR - http://www.scopus.com/inward/record.url?scp=67649213198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649213198&partnerID=8YFLogxK

M3 - Article

C2 - 19579588

AN - SCOPUS:67649213198

VL - 56

SP - 307

EP - 312

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 90

ER -